SCHEMBL862541

SCHEMBL862541

CS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(Cl)ccc2n1Cc1cccc(NS(C)(=O)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.42
PPARG P37231 1/20 0.41
RCE1 Q9Y256 1/20 0.40
MAPK8 P45983 1/20 0.38
TDP2 O95551 1/20 0.38
CYP2C8 P10632 1/20 0.38
MCL1 Q07820 1/20 0.38
MEN1 O00255 2/20 0.38
BRAF P15056 1/20 0.37
PTGDR2 Q9Y5Y4 3/20 0.37
SERPINE1 P05121 2/20 0.37
CCNE2 O96020 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CYP3A4 P08684 1/20 0.36
ROCK1 Q13464 1/20 0.36
CCR2 P41597 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862140 0.93 KMT2A (0.47) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL862296 0.93 PPARG (0.41) KMT2APPARGRCE1MAPK8TDP2
SCHEMBL12673667 0.92 SERPINE1 (0.45) KMT2APPARGRCE1MAPK8TDP2
SCHEMBL862067 0.92 KMT2A (0.50) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL10256439 0.91 KMT2A (0.42) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL862277 0.91 KMT2A (0.45) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL862037 0.91 KMT2A (0.44) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL862125 0.90 KMT2A (0.42) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL862200 0.90 KMT2A (0.42) KMT2APPARGRCE1MAPK8CYP2C8
SCHEMBL832009 0.90 BRD4 (0.39) KMT2APPARGRCE1MAPK8CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 KMT2A 321/4885PPARG 4093/4885RCE1 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.